Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 24,300 shares at $121.57 ($3.0M) on 2024-07-17, disclosed to the SEC on 2024-07-19.
Scheduled sale ($3.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $120.86 | 2,601 | $314K | 10.5% |
| 2 | $120.86 | 2,601 | $314K | 10.5% |
| 3 | $121.57 | 2,100 | $255K | 8.5% |
| 4 | $122.86 | 2,900 | $356K | 11.9% |
| 5 | $123.82 | 6,699 | $829K | 27.8% |
| 6 | $123.82 | 6,699 |
| $829K |
| 27.8% |
| 7 | $124.61 | 700 | $87K | 2.9% |
| Total | $122.90 avg | 24,300 | $3.0M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |